No new responses in Bind Phase II NSCLC study

Bind Therapeutics Inc. (NASDAQ:BIND) lost $2.15 (20%) to $8.40 on Wednesday, giving back most of its recent gains, after reporting no new partial responses from seven additional patients in its Phase II trial of BIND-014 to treat stage III/IV non-small cell lung cancer (NSCLC).

The shares had risen $1.11 to $8.94 on Oct. 30 after the company released an abstract in advance of the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain. In the abstract, Bind said five (15%) of 33 patients who were evaluable at the time had PRs. Among eight patients who tested positive for the K-Ras ( KRAS) mutation, two (25%) had PRs (see BioCentury Extra, Oct. 30). ...